Acute Myeloid Leukemia (non-APL) · line 2 · Gilteritinib monotherapy for R/R FLT3-mutated AML

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-GILTERITINIB-AML`

ID	`IND-AML-2L-GILTERITINIB-FLT3`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ADMIRAL-PERL-2019` `SRC-ELN-AML-2022` `SRC-NCCN-AML-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for R/R FLT3-mutated AML. Bridge-to-alloHCT intent dominant. Ukraine access constraint dominant (not registered). Crenolanib + sorafenib are off-label alternatives if gilteritinib unavailable.

Used By

Algorithms

ALGO-AML-2L - ALGO-AML-2L